Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Gene variant predisposes humans to develop acute myeloid leukemia, says study

Gene variant predisposes humans to develop acute myeloid leukemia, says study

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia may benefit from decitabine drug

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda receives exclusive rights to distribute AML drug in Europe and Asia

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

Epigenetic diagnosis and therapies, a new strategy for treating cancer

Epigenetic diagnosis and therapies, a new strategy for treating cancer

FDA evaluates Phase III randomized trial in acute myeloid leukemia

FDA evaluates Phase III randomized trial in acute myeloid leukemia

Vion Pharmaceuticals files for bankruptcy

Vion Pharmaceuticals files for bankruptcy

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Italian patent issued for NPM1 to test patients with AML

Italian patent issued for NPM1 to test patients with AML

Update on new clinical developments and other initiatives related to Ceplene

Update on new clinical developments and other initiatives related to Ceplene

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

MLL team finds 454 Sequencing technology promising for leukemia genetic characterization

MLL team finds 454 Sequencing technology promising for leukemia genetic characterization

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients